MedinCell S.A. (LON:0ACH)

Market Cap	415.95M
Revenue (ttm)	10.98M
Net Income (ttm)	-26.17M
Shares Out	n/a
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	222
Average Volume	510
Open	14.07
Previous Close	14.09
Day's Range	14.07 - 14.23
52-Week Range	5.75 - 15.57
Beta	1.27
RSI	58.05
Earnings Date	Jun 17, 2025

About MedinCell

MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the ...

• Industry: Pharmaceutical Preparations
• Founded: 2003
• Employees: 134
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ACH

Financial Performance

In 2023, MedinCell's revenue was 11.95 million, a decrease of -12.52% compared to the previous year's 13.66 million. Losses were -25.04 million, -21.78% less than in 2022.

Financial numbers in EUR